QualityDipStocks / Health Care · Biotech
Repligen RGEN
Outside our quality screen, so we don’t track its dips. It’s 9% below its 52-week high.
Outside our quality screen, trading well above our fair value estimate.
- Fair value est.
- $29.90−83%
- Market Value
- forming
- Off 52-wk high
- −9%
- Risk vs market
- Above marketbeta 1.26
4 bullish · 5 bearish See why
Key levels
Every level vs today’s $176.94
- Fair value est.base case$29.90−83.1%
- 52-wk lowlowest close, 1 year$102.87−41.9%
- PriceFri Oct 30 close$176.94you are here
- 52-wk highhighest close, 1 year$194.57+10.0%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 3.0% ±2 points. Bear = 10.5% and 1.0%; bull = 8.5% and 5.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is above even the bull case.
What the price implies To be worth today’s price, RGEN’s free cash flow would need to grow about 36% a year for five years; our estimate uses 3%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much RGEN moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 3.6× the S&P 500’s.
- Beta vs S&P 500
- 1.26
- Volatility
- 46% vs 13% SPY
- Correlation SPY
- 0.35
- Correlation QQQ
- 0.27
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ProfitabilityGross margin widened to 52.3% in FY2025 from 44.0% in FY2023 (SEC filings).
GrowthSales grew 14% to $806M over the last 12 months vs the 12 months before (SEC filings).
Balance sheetNet cash of $307M: cash and short-term investments exceed debt (Sep 30, 2026).
Balance sheetDebt / equity of 0.3×, below the 0.7× median for the 67 Health Care companies we cover.
Top bearish points 5 of 5
ValuationOur DCF fair value estimate is $29.90, 83% below the price.
Balance sheetOperating income covers interest only 0.8× over the last 12 months.
ProfitabilityLost $12M over the last 12 months (net income, SEC filings).
ValuationEV/EBITDA of 101×: a rich multiple of current earnings power.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%.
Who’s talking about it
Notable investors, executives, analysts and public figures on Repligen in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Biotech
All fundamentals
FCF yield 1.1% · ROE -1% · Sales +14%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- 93.8×
- FCF yield
- 1.1%
- EV / EBITDA
- 100.9×
- Price / sales
- 12.42×
- Price / book
- 4.78×
- Market cap
- $10.0Bprice × diluted shares
- Enterprise value
- $9.7B
Growth
- Revenue, 12 months
- $806M
- Sales growth, 12 months
- +13.8%vs the 12 months before
- Sales growth, 3 yrs
- −2.7%/yrfrom FY2022
- Diluted EPS, 12 months
- −$0.21
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$12M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 53.5%
- Operating margin
- 2.3%
- Net margin
- −1.5%
- FCF margin
- 13.2%
- Return on equity
- −1%
- Return on invested capital
- 1%
Balance sheet
- Cash & short-term inv.
- $863M
- Total debt
- $556M
- Net cash
- $307M
- Debt / equity
- 0.27×
- Interest coverage
- 0.8×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $107M
- FCF growth, 12 months
- −3%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +0.0%diluted shares vs a year ago
- Stock-based comp
- $34M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From Repligen’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $29.90 · FCF value $45.48
Assumes 3.0% growth for 5 years (revenue grew -2.7% a year FY22–FY25; floored at 3%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $1.89 a share (trailing 12 months to Sep 30, 2026), from the 10-Q filed Oct 30, 2026. Net cash $307M, not added.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 49 · 5 days 0.0%
The business
FCF $0.1B · Sales +11%
- Free cash flow, 12 months$0.1B
- Free-cash-flow yield1.0%
- Free-cash-flow margin14%
- Gross margin54%
- Operating margin6%
- Return on invested capital2%
- Return on equity−1%
- Sales growth (latest quarter vs year-ago quarter)+11%
- Net debt / EBITDA−1.2×
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
RGEN is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.